ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Mol Cancer Ther. 2021 Aug;20(8):1327-1337. doi: 10.1158/1535-7163.MCT-20-0565. Epub 2021 May 27.
Mol Cancer Ther. 2021.
PMID: 34045226